Log inSign up
AAOIFI No. 21 screening

Is GANX halal?

Gain Therapeutics, Inc.

Doubtful

No clear verdict is possible for Gain Therapeutics, Inc. — data is insufficient or the case is contested in fiqh. As a precaution it is NOT included in the halal list.

Checked: 14 October 2026

Exchange

NASDAQ

Price

1.26

Day

-5.26%

Market cap

$60.1M

Industry

Biotechnology

Sector

Healthcare

What the company does

Gain Therapeutics is a clinical-stage biotech developing GT-02287 (an allosteric regulator, Phase 1b) for Parkinson's disease. Pre-revenue.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $344K ÷ 36-month average market cap $64.33M = 0.5%

    0.5%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $13.08M ÷ 36-month average market cap $64.33M = 20.3%

    20.3%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $60.14M.

For information (AAOIFI 3/1 note): cash + receivables are 91.5% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Superinvestors

SEC 13F, 2026 Q3. Up to 45 days delayed.

Held by 1 superinvestors · Average reported price: $2.03

All superinvestor portfolios

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyGANX's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →